Tiziana Life Sciences is trading at $0.93 (-5.50%) primarily amid a biotech-sector sell-off.
- No new company-specific announcement dated September 1, 2026 was identified.
- Tiziana’s latest official investor update was an August 24 announcement about a poster presentation for its Phase 2a BANYAN trial.
- Biotech ETF XBI is down 4.24%; the stock has fallen from $1.14 on August 21 to $0.93 currently.